Abstract:Abstract Background Lung cancer is the leading cause of cancer-related death worldwide, among which lung adenocarcinoma (LUAD) is the most common type. Identified as a hallmark of cancer, the dysregulated cell cycle progression plays an important role in the promotion and progression of LUAD. This article aims to elucidate the heterogeneity between CDKN2A-CDK/cyclin-RB1 cell cycle progression pathway altered /non-altered patients with LUAD, thus helping us have a better understanding of the effect of the aberrant cell cycle. Material and Methods The data of this study were downloaded from The Cancer Genome Atlas (TCGA) data portal (https://portal.gdc.cancer.gov/) and UCSC Xena Browser (http://xena.ucsc.edu/), including simple nucleotide variation data, RNA-seq gene expression data, survival data, clinical data, and miRNA expression data. After matching the RNA-seq gene expression data, simple nucleotide variation data, miRNA expression data, and survival data with clinical data, 510 gene and long non-coding RNA expression data, 506 simple nucleotide variation data, 440 microRNA expression data, and 497 survival data were included in this study for further analysis. R software (version 4.0.3) was used for analysis. Results After dividing the patients into mutation (n = 57) and wild (n = 453) groups according to the cell cycle progression pathway status, we found no significant difference in survivorship between them. The mutation group had a higher mutational load and mutational rates of various genes such as tumor protein P53 (TP53) compared to the wild group. Subsequently, we analyzed the differentially expressed genes (DEGs) between the two groups. Among the 58387 genes analyzed, 302 were upregulated, and 354 were downregulated in the mutation group. Enrichment analysis indicated that these DEGs were closely related to metabolism items and cell cycle-related events. After performing immune cell infiltration analysis, we found the two groups have different patterns of immune cell profiling. Albeit the immune and stromal scores were higher in the wild group, we failed to find any significant difference between the two groups. Finally, we build a computational model to predict the cell cycle progression pathway-related gene mutation by LASSO-binary logistic regression analysis, the predictive accuracy of which is 0.88. Conclusion In summary, our study compared the genetic and microenvironment differences between cell cycle progression pathway altered /non-altered patients with LUAD by analyzing the data from TCGA datasets. We hope our findings could improve our understanding of the heterogeneity between the two kinds of patients, thus providing new insight into LUAD patients' treatments.

P1.03-05 Transcriptome Landscape of Lung Adenocarcinoma Patients Revealed Distinct Trajectory Patterns

Cell Trajectory-Related Genes of Lung Adenocarcinoma Predict Tumor Immune Microenvironment and Prognosis of Patients

Identification of Genes Associated with Lung Adenocarcinoma Prognosis

P02.05 Comprehensive Profiling of Tumor Heterogeneity and Its Microenvironment in Advanced Non-Small Cell Lung Cancer at Single Cell Resolution

Characterizing Tumor Microenvironment and Risk Genes in Lung Adenocarcinoma through scRNA-seq and Bulk RNA-seq Data

Exploring The Effect Of Differentially Expressed Long Non-Coding Rnas Driven By Copy Number Variation On Competing Endogenous Rna Network By Mining Lung Adenocarcinoma Data

Up-regulated tumor intrinsic growth potential and decreased immune function orchestrate the evolution of lung adenocarcinoma

Genetic and tumor microenvironment differences between cell cycle progression pathway altered/non-altered patients with lung adenocarcinoma

Single-cell Transcriptome Analysis Demonstrates Inter-Patient and Intra-Tumor Heterogeneity in Primary and Metastatic Lung Adenocarcinoma

Abstract 6935: Non-genetic routes of lung cancer evolution

Identification of Stage-Specific Biomarkers in Lung Adenocarcinoma Based on Rna-Seq Data

Integrated single-cell RNA sequencing analysis reveals distinct cellular and transcriptional modules associated with survival in lung cancer

Transcriptomic Analyses of the Adenoma-Carcinoma Sequence Identify Hallmarks Associated with the Onset of Colorectal Cancer

Varied Pathways of Stage Ia Lung Adenocarcinomas Discovered by Integrated Gene Expression Analysis

Genome-wide Analyses of Long Noncoding RNA Expression Profiles in Lung Adenocarcinoma

Large-scale RNA-Seq Transcriptome Analysis of 4043 Cancers and 548 Normal Tissue Controls across 12 TCGA Cancer Types

Identification of Key Genes with Differential Correlations in Lung Adenocarcinoma

Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populations in early-stage lung adenocarcinomas harboring EGFR mutations

Characterization of the evolution trajectory and immune profiling of new histologic patterns in lung adenocarcinoma

Abstract 3292: Revisiting TCGA data identifies key genes in lung adenocarcinoma

Spatiotemporal Profiling Unveiling the Cellular Organization Patterns and Local Protumoral Immune Microenvironment Remodeling in Early Lung Adenocarcinoma Progression